Bharat Biotech

iNCOVACC is the world’s first intra-nasal vaccine for COVID to receive approval for the primary two-dose schedule, and…

Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year,…

Incovacc is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein

BBV154 is an intra-nasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine

Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria

Data from both phase-III human clinical trials have been submitted for approval to National Regulatory Authorities

The Drug Controller General of India (DCGI) gave its nod to conduct clinical trials for Bharat Biotech’s intranasal vaccine as…

Subjects were evaluated for safety, neutralising antibody responses against variants of concern, binding antibodies against spike…

Ocugen’s partner Bharat Biotech’s phase-II/III study of Covaxin (BBV152) in 526 children showed safety, efficacy, and superior…

The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge were observed…